cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Applied Therapeutics Inc
5 own
12 watching
Current Price
$1.3
$-0.04
(-2.99%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
39.28M
52-Week High
52-Week High
2.18
52-Week Low
52-Week Low
0.4995
Average Volume
Average Volume
0.13M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization39.28M
icon52-Week High2.18
icon52-Week Low0.4995
iconAverage Volume0.13M
iconDividend Yield--
iconP/E Ratio--
What does the Applied Therapeutics Inc do?
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.
Read More
How much money does Applied Therapeutics Inc make?
News & Events about Applied Therapeutics Inc.
PR Newswire
5 months ago
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Applied Therapeutics, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Applied Therapeutics, Inc. for Potential Breaches of Fiduciary Duty...
Globe Newswire
9 months ago
Completed public equity offering with gross proceeds of $30 million Granted orphan medicinal product designation by the EMA for AT-007 for treatment of Galactosemia Continued progress in three registrational Phase 3 trials in areas of high unmet medical need, with multiple clinical milestones ...
Globe Newswire
11 months ago
NEW YORK, June 22, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ: APLT) (the Company), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced the pricing of...
Globe Newswire
12 months ago
NEW YORK, June 03, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced designation of AT-007 (...
Globe Newswire
1 year ago
NEW YORK, March 25, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Corcept Therapeutics, Inc. (NASDAQ: CORT), Verra Mobility Corp. (NASDAQ: VRRM), Core Scientific, Inc. (NASDAQ: CORZ), and Applied ...
Frequently Asked Questions
Frequently Asked Questions
What is Applied Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Applied Therapeutics Inc shares?
plus_minus_icon
How can I buy Applied Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Applied Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Applied Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Applied Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Applied Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Applied Therapeutics Inc?
plus_minus_icon
What percentage is Applied Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Applied Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$1.3
$-0.04
(-2.99%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
PRAXIS PRECISION MEDICINES I
PRAXIS PRECISION MEDICINES I
$1.00
$-0.01 (-1.48 %)
ALIGOS THERAPEUTICS INC
ALIGOS THERAPEUTICS INC
$1.12
$0.02 (1.82 %)
Surface Oncology Inc
Surface Oncology Inc
$0.81
$0.06 (8.28 %)
Magenta Therapeutics Inc
Magenta Therapeutics Inc
$0.64
$0.01 (1.59 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
PRAXIS PRECISION MEDICINES I
PRAXIS PRECISION MEDICINES I
$1.00
$-0.01 (-1.48 %)
ALIGOS THERAPEUTICS INC
ALIGOS THERAPEUTICS INC
$1.12
$0.02 (1.82 %)
Surface Oncology Inc
Surface Oncology Inc
$0.81
$0.06 (8.28 %)
Magenta Therapeutics Inc
Magenta Therapeutics Inc
$0.64
$0.01 (1.59 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00